Format

Send to

Choose Destination
World J Gastroenterol. 2015 Nov 21;21(43):12322-33. doi: 10.3748/wjg.v21.i43.12322.

Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications.

Author information

1
Francesca Romana Ponziani, Viviana Gerardi, Silvia Pecere, Francesca D'Aversa, Loris Lopetuso, Maria Assunta Zocco, Maurizio Pompili, Antonio Gasbarrini, Internal Medicine and Gastroenterology, Agostino Gemelli Hospital, 00168 Rome, Italy.

Abstract

Liver cirrhosis is a paradigm of intestinal dysbiosis. The qualitative and quantitative derangement of intestinal microbial community reported in cirrhotic patients seems to be strictly related with the impairment of liver function. A kind of gut microbial "fingerprint", characterized by the reduced ratio of "good" to "potentially pathogenic" bacteria has recently been outlined, and is associated with the increase in Model for End-Stage Liver Disease and Child Pugh scores. Moreover, in patients presenting with cirrhosis complications such as spontaneous bacterial peritonitis (SBP), hepatic encephalopathy (HE), and, portal hypertension intestinal microbiota modifications or the isolation of bacteria deriving from the gut are commonly reported. Rifaximin is a non-absorbable antibiotic used in the management of several gastrointestinal diseases. Beyond bactericidal/bacteriostatic, immune-modulating and anti-inflammatory activity, a little is known about its interaction with gut microbial environment. Rifaximin has been demonstrated to exert beneficial effects on cognitive function in patients with HE, and also to prevent the development of SBP, to reduce endotoxemia and to improve hemodynamics in cirrhotics. These results are linked to a shift in gut microbes functionality, triggering the production of favorable metabolites. The low incidence of drug-related adverse events due to the small amount of circulating drug makes rifaximin a relatively safe antibiotic for the modulation of gut microbiota in advanced liver disease.

KEYWORDS:

Ascites; Endotoxemia; Gut microbiota; Hepatic encephalopathy; Liver cirrhosis; Rifaximin; Spontaneous bacterial peritonitis; Thrombocytopenia

PMID:
26604640
PMCID:
PMC4649116
DOI:
10.3748/wjg.v21.i43.12322
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Baishideng Publishing Group Inc. Icon for PubMed Central
Loading ...
Support Center